The First WHO International Standard for Adalimumab: Dual Role in Bioactivity and Therapeutic Drug Monitoring

The First WHO International Standard for Adalimumab: Dual Role in Bioactivity and Therapeutic Drug Monitoring

The expanded availability of adalimumab products continues to widen patient access and reduce costs with substantial benefit to healthcare systems. However, the long-term success of these medicines is highly dependent on maintaining consistency in quality, safety and efficacy while minimizing any ri...

Full description

Bibliographic Details
Main Authors:	Meenu Wadhwa, Chris Bird, Eleanor Atkinson, Isabelle Cludts, Peter Rigsby
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-04-01
Series:	Frontiers in Immunology
Subjects:	international standard biosimilars potency clinical monitoring unit product life-cycle
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2021.636420/full

Similar Items

The First WHO International Standard for Harmonizing the Biological Activity of Bevacizumab
by: Haiyan Jia, et al.
Published: (2021-10-01)

Cost per responder of adalimumab biosimilars versus methotrexate in patients with psoriasis: a real-life experience
by: Martina Maurelli, et al.
Published: (2023-12-01)

Iraqi Registry Data Proves Safety and Efficacy of switching to Adalimumab Biosimilar in Treating Rheumatoid Arthritis
by: Yasameen Abbas, et al.
Published: (2024-12-01)

Effects of Adalimumab-adbm Versus Adalimumab Reference Product on Patient-Reported Outcomes in Rheumatoid Arthritis: Results from VOLTAIRE-RA
by: Vibeke Strand, et al.
Published: (2024-08-01)

Efficacy and safety evaluations of adalimumab biosimilars in the treatment of psoriasis
by: Changkun Li, et al.
Published: (2023-12-01)

Summary of Research: Effects of Adalimumab-adbm Versus Adalimumab Reference Product on Patient-Reported Outcomes in Rheumatoid Arthritis: Results from VOLTAIRE-RA
by: Vibeke Strand
Published: (2024-08-01)

Adalimumab Biosimilar GP2017 versus Adalimumab Originator in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study
by: Giammarco Mocci, et al.
Published: (2022-07-01)

A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis
by: Roy M. Fleischmann, et al.
Published: (2018-08-01)

Adalimumab Originator vs. Biosimilar in Hidradenitis Suppurativa: A Multicentric Retrospective Study
by: Martina Burlando, et al.
Published: (2022-10-01)

Volume and trends of adalimumab and pembrolizumab reimbursed market: the Bulgarian perspective
by: Maria Kamusheva, et al.
Published: (2021-01-01)

A Budget impact analysis of adalimumab biosimilar: the Italian context
by: Roberto Ravasio, et al.
Published: (2019-05-01)

An Update Review of Biosimilars of Adalimumab in Psoriasis – Bioequivalence and Interchangeability
by: Zhou X, et al.
Published: (2021-07-01)

The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures
by: Evelien Moorkens, et al.
Published: (2021-01-01)

Real-Life Tolerability and Effectiveness of Adalimumab Biosimilar in Rheumatoid Arthritis: ASPIRE Registry Data
by: Sanjiv Kapoor, et al.
Published: (2019-06-01)

Physicochemical analysis and biological characterization of FKB327 as a biosimilar to adalimumab
by: Stefan Schreiber, et al.
Published: (2020-06-01)

Pharmacokinetics, safety, and immunogenicity of HLX03, an adalimumab biosimilar, compared with reference biologic in healthy Chinese male volunteers: Results of a randomized, double‐blind, parallel‐controlled, phase 1 study
by: Hong Zhang, et al.
Published: (2021-04-01)

Identifying Fields for Merger and Acquisitions in the Agricultural Production Cooperatives in Iran
by: Mohammad Zarei, et al.
Published: (2014-08-01)

A prospective, randomized, double-blind, comparative clinical study of efficacy and safety of a biosimilar adalimumab with innovator product in patients with active rheumatoid arthritis on a stable dose of methotrexate
by: Prasad Apsangikar, et al.
Published: (2018-01-01)

A Phase I, Randomized, Single-Dose Study to Evaluate the Biosimilarity of HOT-3010 to Adalimumab Among Healthy Chinese Male Subjects
by: Hong Zhang, et al.
Published: (2021-03-01)

The impact of EU public procurement regulations on tenders in Spain: a study with adalimumab
by: F. J. Esplugues, et al.
Published: (2024-09-01)

Navigating adalimumab biosimilars: an expert opinion
by: Vered Abitbol, et al.
Published: (2023-10-01)

A New Model to Calibrate a Reference Standard for Bovine Tuberculin Purified Protein Derivative in the Target Species
by: Klaas Frankena, et al.
Published: (2018-10-01)

Comparative efficacy and safety of adalimumab biosimilar (BCD-057) and innovator in patients with psoriasis vulgaris. Results of the BCD-057-2/CALYPSO phase III international, multicenter, randomized double-blind clinical trial
by: Т. V. Korotaeva, et al.
Published: (2018-12-01)

Type and Extent of Information on (Potentially Critical) Quality Attributes Described in European Public Assessment Reports for Adalimumab Biosimilars
by: Ali M. Alsamil, et al.
Published: (2021-02-01)

International standards for monoclonal antibodies for assessing the biological activity of medicines: A status update
by: L. A. Gayderova, et al.
Published: (2023-12-01)

Population Pharmacokinetic Analysis and Simulation of Alternative Dosing Regimens for Biosimilars to Adalimumab and Etanercept in Patients with Rheumatoid Arthritis
by: Stephanie F. Ling, et al.
Published: (2024-05-01)

Treatment Persistence and Switching Patterns of Adalimumab Biosimilar ABP 501 in European Patients with Rheumatologic Diseases
by: Ran Jin, et al.
Published: (2024-03-01)

Quality assessment strategy development and analytical method selection of GMP grade biological drugs for gene and cell therapy
by: Quan-en Yang, et al.
Published: (2025-01-01)

Authorisation of Non-Innovator Biotherapeutic (Biosimilar) Products in the USA
by: A. A. Soldatov, et al.
Published: (2019-03-01)

Differential retention of adalimumab and etanercept biosimilars compared to originator treatments: Results of a retrospective French multicenter study
by: Guillaume Larid, et al.
Published: (2022-10-01)

Optimization of bioactive compounds extraction from olive pomace by microwave hydro diffusion and gravity
by: Vanessa Sabrina Fagundes Batista, et al.
Published: (2024-10-01)

Efficacy and Safety of Adalimumab Biosimilars: Current Critical Clinical Data in Rheumatoid Arthritis
by: XiaoQin Lu, et al.
Published: (2021-04-01)

Summary of Research: Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial
by: Alan Menter
Published: (2023-10-01)

Same but different? A thematic analysis on adalimumab biosimilar switching among patients with juvenile idiopathic arthritis
by: William D. Renton, et al.
Published: (2019-10-01)

Physicochemical and biological similarity assessment of LBAL, a biosimilar to adalimumab reference product (Humira®)
by: Joon-Cheol Kwon, et al.
Published: (2021-06-01)

Research progress on substitution of in vivo method(s) by in vitro method(s) for human vaccine potency assays
by: Xuanxuan Zhang, et al.
Published: (2023-12-01)

Sustainability of Biosimilars in Europe: A Delphi Panel Consensus with Systematic Literature Review
by: Arnold G. Vulto, et al.
Published: (2020-11-01)

Biosimilars and Switching: What Is Your Perspective?
by: Sandoz
Published: (2017-08-01)

Comparison of Efficacy and Safety of Original and Biosimilar Adalimumab in Active Rheumatoid Arthritis in a Real-World National Cohort
by: Claudiu Costinel Popescu, et al.
Published: (2022-12-01)

Efficacy And Safety Of Adalimumab Biosimilar (Exemptia) In Moderate-To-Severe Steroid-Refractory Ulcerative Colitis Patients: Real-Life Outcomes In Resource-Constrained Setting At 24-Weeks Follow-Up
by: Chandra A, et al.
Published: (2019-11-01)